Study #2021-0854
MK-6482: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab, Belzutifan, Lenvatinib
Description
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Carcinoma, Hepatocellular, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma, Biliary Tract Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms
Study phase:
Phase II
Physician name:
Brandon Smaglo
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-844-996-5012
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.